Sarepta therapeutics provides update on elevidys

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, shared the following update related to elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with duchenne muscular dystrophy. following the safety update on acute liver failure that was issued on march 18, european union (eu) reference member country authorities requested that the independent data monitoring committee (dmc).
SRPT Ratings Summary
SRPT Quant Ranking